Usha Menon

List of Publications by Year
in descending order

358 papers	25,987 citations	10986 71 h-index	8866 145 g-index
374 all docs	374 docs citations	374 times ranked	28361 citing authors

#	Article	IF	Citations
1	Association analysis identifies 65 new breast cancer risk loci. Nature, 2017, 551, 92-94.	27.8	1,099
2	Rethinking ovarian cancer: recommendations for improving outcomes. Nature Reviews Cancer, 2011, 11, 719-725.	28.4	1,084
3	Rethinking ovarian cancer II: reducing mortality from high-grade serous ovarian cancer. Nature Reviews Cancer, 2015, 15, 668-679.	28.4	839
4	Ovarian cancer screening and mortality in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet, The, 2016, 387, 945-956.	13.7	791
5	Association between endometriosis and risk of histological subtypes of ovarian cancer: a pooled analysis of caseâ€“control studies. Lancet Oncology, The, 2012, 13, 385-394.	10.7	753
6	Age-dependent DNA methylation of genes that are suppressed in stem cells is a hallmark of cancer. Genome Research, 2010, 20, 440-446.	5.5	740
7	Sensitivity and specificity of multimodal and ultrasound screening for ovarian cancer, and stage distribution of detected cancers: results of the prevalence screen of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Lancet Oncology, The, 2009, 10, 327-340.	10.7	738
8	Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes. American Journal of Human Genetics, 2019, 104, 21-34.	6.2	711
9	Screening for ovarian cancer: a pilot randomised controlled trial. Lancet, The, 1999, 353, 1207-1210.	13.7	545
10	Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer. Nature Genetics, 2013, 45, 371-384.	21.4	493
11	Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet, The, 2003, 362, 1871-1876.	13.7	467
12	New tumor markers: CA125 and beyond. International Journal of Gynecological Cancer, 2005, 15, 274-281.	2.5	424
13	Progress and Challenges in Screening for Early Detection of Ovarian Cancer. Molecular and Cellular Proteomics, 2004, 3, 355-366.	3.8	375
14	Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer. Nature Genetics, 2017, 49, 680-691.	21.4	356
15	Hormone-receptor expression and ovarian cancer survival: an Ovarian Tumor Tissue Analysis consortium study. Lancet Oncology, The, 2013, 14, 853-862.	10.7	335
16	GWAS meta-analysis and replication identifies three new susceptibility loci for ovarian cancer. Nature Genetics, 2013, 45, 362-370.	21.4	326
17	A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nature Genetics, 2010, 42, 874-879.	21.4	321
18	Ovarian cancer population screening and mortality after long-term follow-up in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a randomised controlled trial. Lancet, The, 2021, 397, 2182-2193.	13.7	313

#	Article	IF	Citations
19	Germline Mutations in the BRIP1, BARD1, PALB2, and NBN Genes in Women With Ovarian Cancer. Journal of the National Cancer Institute, 2015, 107, .	6.3	311
20	Causal Associations of Adiposity and Body Fat Distribution With Coronary Heart Disease, Stroke Subtypes, and Type 2 Diabetes Mellitus. Circulation, 2017, 135, 2373-2388.	1.6	304
21	An Epigenetic Signature in Peripheral Blood Predicts Active Ovarian Cancer. PLoS ONE, 2009, 4, e8274.	2.5	291
22	A genome-wide association study identifies a new ovarian cancer susceptibility locus on 9p22.2. Nature Genetics, 2009, 41, 996-1000.	21.4	276
23	Contribution of Germline Mutations in the RAD51B, RAD51C, and RAD51D Genes to Ovarian Cancer in the Population. Journal of Clinical Oncology, 2015, 33, 2901-2907.	1.6	266
24	Genome-wide association study identifies 32 novel breast cancer susceptibility loci from overall and subtype-specific analyses. Nature Genetics, 2020, 52, 572-581.	21.4	265
25	Dose-Response Association of CD8⁺ Tumor-Infiltrating Lymphocytes and Survival Time in High-Grade Serous Ovarian Cancer. JAMA Oncology, 2017, 3, e173290.	7.1	260
26	Development of a Multimarker Assay for Early Detection of Ovarian Cancer. Journal of Clinical Oncology, 2010, 28, 2159-2166.	1.6	246
27	Identification of six new susceptibility loci for invasive epithelial ovarian cancer. Nature Genetics, 2015, 47, 164-171.	21.4	221
28	Calculation of the Risk of Ovarian Cancer From Serial CA-125 Values for Preclinical Detection in Postmenopausal Women. Journal of Clinical Oncology, 2003, 21, 206s-210.	1.6	219
29	Prospective Study Using the Risk of Ovarian Cancer Algorithm to Screen for Ovarian Cancer. Journal of Clinical Oncology, 2005, 23, 7919-7926.	1.6	218
30	Cancer survivors information seeking behaviors: A comparison of survivors who do and do not seek information about cancer. Patient Education and Counseling, 2007, 65, 342-350.	2.2	195
31	Aspirin, Nonaspirin Nonsteroidal Anti-inflammatory Drug, and Acetaminophen Use and Risk of Invasive Epithelial Ovarian Cancer: A Pooled Analysis in the Ovarian Cancer Association Consortium. Journal of the National Cancer Institute, 2014, 106, djt431-djt431.	6.3	186
32	A transcriptome-wide association study of 229,000 women identifies new candidate susceptibility genes for breast cancer. Nature Genetics, 2018, 50, 968-978.	21.4	184
33	Sensitivity of transvaginal ultrasound screening for endometrial cancer in postmenopausal women: a case-control study within the UKCTOCS cohort. Lancet Oncology, The, 2011, 12, 38-48.	10.7	176
34	Ovarian Cancer Prevention and Screening. Obstetrics and Gynecology, 2018, 131, 909-927.	2.4	176
35	Obesity and risk of ovarian cancer subtypes: evidence from the Ovarian Cancer Association Consortium. Endocrine-Related Cancer, 2013, 20, 251-262.	3.1	169
36	Risk Algorithm Using Serial Biomarker Measurements Doubles the Number of Screen-Detected Cancers Compared With a Single-Threshold Rule in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. Journal of Clinical Oncology, 2015, 33, 2062-2071.	1.6	166

#	Article	IF	Citations
37	Serum CA19-9 Is Significantly Upregulated up to 2 Years before Diagnosis with Pancreatic Cancer: Implications for Early Disease Detection. Clinical Cancer Research, 2015, 21, 622-631.	7.0	158
38	Genome-Wide Meta-Analyses of Breast, Ovarian, and Prostate Cancer Association Studies Identify Multiple New Susceptibility Loci Shared by at Least Two Cancer Types. Cancer Discovery, 2016, 6, 1052-1067.	9.4	157
39	The Manchester International Consensus Group recommendations for the management of gynecological cancers in Lynch syndrome. Genetics in Medicine, 2019, 21, 2390-2400.	2.4	153
40	Evidence of Stage Shift in Women Diagnosed With Ovarian Cancer During Phase II of the United Kingdom Familial Ovarian Cancer Screening Study. Journal of Clinical Oncology, 2017, 35, 1411-1420.	1.6	148
41	Population Testing for Cancer Predisposing BRCA1/BRCA2 Mutations in the Ashkenazi-Jewish Community: A Randomized Controlled Trial. Journal of the National Cancer Institute, 2015, 107, 379.	6.3	146
42	Epigenetic analysis leads to identification of HNF1B as a subtype-specific susceptibility gene for ovarian cancer. Nature Communications, 2013, 4, 1628.	12.8	144
43	Cost-effectiveness of Population-Based BRCA1, BRCA2, RAD51C, RAD51D, BRIP1, PALB2 Mutation Testing in Unselected General Population Women. Journal of the National Cancer Institute, 2018, 110, 714-725.	6.3	138
44	Cost-effectiveness of Population Screening for BRCA Mutations in Ashkenazi Jewish Women Compared With Family Historyâ€“Based Testing. Journal of the National Cancer Institute, 2015, 107, 380.	6.3	135
45	Preanalytic Influence of Sample Handling on SELDI-TOF Serum Protein Profiles. Clinical Chemistry, 2007, 53, 645-656.	3.2	131
46	Epigenotyping in Peripheral Blood Cell DNA and Breast Cancer Risk: A Proof of Principle Study. PLoS ONE, 2008, 3, e2656.	2.5	131
47	Recruitment to multicentre trials–lessons from UKCTOCS: descriptive study. BMJ: British Medical Journal, 2008, 337, a2079-a2079.	2.3	128
48	Results of Annual Screening in Phase I of the United Kingdom Familial Ovarian Cancer Screening Study Highlight the Need for Strict Adherence to Screening Schedule. Journal of Clinical Oncology, 2013, 31, 49-57.	1.6	126
49	Development of a self-efficacy scale for mammography. Research in Nursing and Health, 2005, 28, 329-336.	1.6	123
50	The potential of circulating tumor DNA methylation analysis for the early detection and management of ovarian cancer. Genome Medicine, 2017, 9, 116.	8.2	122
51	Views of BRCA gene mutation carriers on preimplantation genetic diagnosis as a reproductive option for hereditary breast and ovarian cancer. Human Reproduction, 2007, 22, 1573-1577.	0.9	118
52	Ovarian cancer screeningâ€"Current status, future directions. Gynecologic Oncology, 2014, 132, 490-495.	1.4	115
53	Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status. BJOG: an International Journal of Obstetrics and Gynaecology, 2011, 118, 814-824.	2.3	114
54	Association of vitamin D levels and risk of ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 1619-1630.	1.9	111

#	Article	IF	Citations
55	Ovarian and Breast Cancer Risks Associated With Pathogenic Variants in RAD51C and RAD51D. Journal of the National Cancer Institute, 2020, 112, 1242-1250.	6.3	106
56	Prevalence, frequency and problem rating of hot flushes persist in older postmenopausal women: impact of age, body mass index, hysterectomy, hormone therapy use, lifestyle and mood in a crossâ€sectional cohort study of 10â€ƒ418 British women aged 54â€“65. BJOG: an International Journal of Obstetrics and Gynaecology, 2012, 119, 40-50.	2.3	105
57	Health Behaviors in Cancer Survivors. Oncology Nursing Forum, 2007, 34, 643-651.	1.2	102
58	The sex hormone system in carriers of BRCA1/2 mutations: a case-control study. Lancet Oncology, The, 2013, 14, 1226-1232.	10.7	98
59	Identification and molecular characterization of a new ovarian cancer susceptibility locus at 17q21.31. Nature Communications, 2013, 4, 1627.	12.8	98
60	Microarray Glycoprofiling of CA125 Improves Differential Diagnosis of Ovarian Cancer. Journal of Proteome Research, 2013, 12, 1408-1418.	3.7	96
61	Recent developments in ovarian cancer screening. Current Opinion in Obstetrics and Gynecology, 2000, 12, 39-42.	2.0	95
62	Surgical morbidity associated with radical trachelectomy and radical hysterectomy. Gynecologic Oncology, 2006, 101, 450-454.	1.4	91
63	Genome-wide association and transcriptome studies identify target genes and risk loci for breast cancer. Nature Communications, 2019, 10, 1741.	12.8	90
64	Testing breast cancer serum biomarkers for early detection and prognosis in pre-diagnosis samples. British Journal of Cancer, 2017, 116, 501-508.	6.4	86
65	Prognostic gene expression signature for high-grade serous ovarian cancer. Annals of Oncology, 2020, 31, 1240-1250.	1.2	85
66	Cigarette smoking and risk of ovarian cancer: a pooled analysis of 21 caseâ€“control studies. Cancer Causes and Control, 2013, 24, 989-1004.	1.8	84
67	Evaluation of serum CEA, CYFRA21-1 and CA125 for the early detection of colorectal cancer using longitudinal preclinical samples. British Journal of Cancer, 2015, 113, 268-274.	6.4	84
68	Population Distribution of Lifetime Risk of Ovarian Cancer in the United States. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 671-676.	2.5	82
69	Associations of obesity and circulating insulin and glucose with breast cancer risk: a Mendelian randomization analysis. International Journal of Epidemiology, 2019, 48, 795-806.	1.9	81
70	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breastâ€“ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	12.8	78
71	Appraising the role of previously reported risk factors in epithelial ovarian cancer risk: A Mendelian randomization analysis. PLoS Medicine, 2019, 16, e1002893.	8.4	78
72	BRCA2 Polymorphic Stop Codon K3326X and the Risk of Breast, Prostate, and Ovarian Cancers. Journal of the National Cancer Institute, 2016, 108, djv315.	6.3	77

#	Article	IF	Citations
73	Evidence for a time-dependent association between FOLR1 expression and survival from ovarian carcinoma: implications for clinical testing. An Ovarian Tumour Tissue Analysis consortium study. British Journal of Cancer, 2014, 111, 2297-2307.	6.4	76
74	ESR1/SYNE1 Polymorphism and Invasive Epithelial Ovarian Cancer Risk: An Ovarian Cancer Association Consortium Study. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 245-250.	2.5	75
75	LIN28B Polymorphisms Influence Susceptibility to Epithelial Ovarian Cancer. Cancer Research, 2011, 71, 3896-3903.	0.9	75
76	Consortium analysis of 7 candidate SNPs for ovarian cancer. International Journal of Cancer, 2008, 123, 380-388.	5.1	73
77	Early detection of cancer in the general population: a blinded caseâ€“control study of p53 autoantibodies in colorectal cancer. British Journal of Cancer, 2013, 108, 107-114.	6.4	73
78	Steroid hormone measurements from different types of assays in relation to body mass index and breast cancer risk in postmenopausal women: Reanalysis of eighteen prospective studies. Steroids, 2015, 99, 49-55.	1.8	71
79	Adult body mass index and risk of ovarian cancer by subtype: a Mendelian randomization study. International Journal of Epidemiology, 2016, 45, 884-895.	1.9	71
80	Biomarker-Based Ovarian Carcinoma Typing: A Histologic Investigation in the Ovarian Tumor Tissue Analysis Consortium. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 1677-1686.	2.5	70
81	Association of p16 expression with prognosis varies across ovarian carcinoma histotypes: an Ovarian Tumor Tissue Analysis consortium study. Journal of Pathology: Clinical Research, 2018, 4, 250-261.	3.0	70
82	Beliefs Associated With Fecal Occult Blood Test and Colonoscopy Use at a Worksite Colon Cancer Screening Program. Journal of Occupational and Environmental Medicine, 2003, 45, 891-898.	1.7	69
83	Screening for Ovarian Cancer. Clinical Obstetrics and Gynecology, 2006, 49, 433-447.	1.1	69
84	Decreased Serum Thrombospondin-1 Levels in Pancreatic Cancer Patients Up to 24 Months Prior to Clinical Diagnosis: Association with Diabetes Mellitus. Clinical Cancer Research, 2016, 22, 1734-1743.	7.0	69
85	Prevalence and predictors of complementary and alternative medicine/non-pharmacological interventions use for menopausal symptoms within the UK Collaborative Trial of Ovarian Cancer Screening. Climacteric, 2017, 20, 240-247.	2.4	69
86	Shared genetics underlying epidemiological association between endometriosis and ovarian cancer. Human Molecular Genetics, 2015, 24, 5955-5964.	2.9	68
87	Ovarian cancer screening: Current status and future directions. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2020, 65, 32-45.	2.8	68
88	Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. BJOG: an International Journal of Obstetrics and Gynaecology, 2000, 107, 165-169.	2.3	64
89	Risk of epithelial ovarian cancer in asymptomatic women with ultrasoundâ€detected ovarian masses: a prospective cohort study within the UK collaborative trial of ovarian cancer screening (UKCTOCS). Ultrasound in Obstetrics and Gynecology, 2012, 40, 338-344.	1.7	64
90	Cis-eQTL analysis and functional validation of candidate susceptibility genes for high-grade serous ovarian cancer. Nature Communications, 2015, 6, 8234.	12.8	63

#	Article	IF	Citations
91	Cost-effectiveness of population based BRCA testing with varying Ashkenazi Jewish ancestry. American Journal of Obstetrics and Gynecology, 2017, 217, 578.e1-578.e12.	1.3	63
92	Improved early detection of ovarian cancer using longitudinal multimarker models. British Journal of Cancer, 2020, 122, 847-856.	6.4	60
93	HOXA methylation in normal endometrium from premenopausal women is associated with the presence of ovarian cancer: A proof of principle study. International Journal of Cancer, 2009, 125, 2214-2218.	5.1	59
94	Specifying the ovarian cancer risk threshold of â€˜premenopausal risk-reducing salpingo-oophorectomyâ€™ for ovarian cancer prevention: a cost-effectiveness analysis. Journal of Medical Genetics, 2016, 53, 591-599.	3.2	57
95	Epigenetic reprogramming of fallopian tube fimbriae in BRCA mutation carriers defines early ovarian cancer evolution. Nature Communications, 2016, 7, 11620.	12.8	56
96	Ultrasound assessment of ovarian cancer risk in postmenopausal women with CA125 elevation. British Journal of Cancer, 1999, 80, 1644-1647.	6.4	54
97	Common alleles in candidate susceptibility genes associated with risk and development of epithelial ovarian cancer. International Journal of Cancer, 2011, 128, 2063-2074.	5.1	54
98	Combined and Interactive Effects of Environmental and GWAS-Identified Risk Factors in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 880-890.	2.5	54
99	Ruralâ€“Urban Disparities in Time to Diagnosis and Treatment for Colorectal and Breast Cancer. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 1036-1046.	2.5	54
100	A combination of the immunohistochemical markers CK7 and SATB2 is highly sensitive and specific for distinguishing primary ovarian mucinous tumors from colorectal and appendiceal metastases. Modern Pathology, 2019, 32, 1834-1846.	5.5	54
101	Factors influencing uptake and timing of risk reducing salpingoâ€oophorectomy in women at risk of familial ovarian cancer: a competing risk time to event analysis. BJOG: an International Journal of Obstetrics and Gynaecology, 2012, 119, 527-536.	2.3	53
102	A BRCA1-mutation associated DNA methylation signature in blood cells predicts sporadic breast cancer incidence and survival. Genome Medicine, 2014, 6, 47.	8.2	53
103	Factors influencing serum CA125II levels in healthy postmenopausal women. Cancer Epidemiology Biomarkers and Prevention, 2001, 10, 489-93.	2.5	53
104	Ovarian and cervical cancer awareness: development of two validated measurement tools. Journal of Family Planning and Reproductive Health Care, 2012, 38, 167-174.	0.8	52
105	Autoantibodies to MUC1 glycopeptides cannot be used as a screening assay for early detection of breast, ovarian, lung or pancreatic cancer. British Journal of Cancer, 2013, 108, 2045-2055.	6.4	52
106	Serum Peptide Profiling using MALDI Mass Spectrometry. Proteomics, 2007, 7, 77-89.	2.2	51
107	Ovarian cancer screening in the general population: current status. International Journal of Gynecological Cancer, 2001, 11, 3-6.	2.5	49
108	Vitamin D receptor rs2228570 polymorphism and invasive ovarian carcinoma risk: Pooled analysis in five studies within the Ovarian Cancer Association Consortium. International Journal of Cancer, 2011, 128, 936-943.	5.1	49

#	Article	IF	Citations
109	Predictive Value of Symptoms for Ovarian Cancer: Comparison of Symptoms Reported by Questionnaire, Interview, and General Practitioner Notes. Journal of the National Cancer Institute, 2012, 104, 114-124.	6.3	49
110	Cancerâ€associated autoantibodies to MUC1 and MUC4â€"A blinded caseâ€"control study of colorectal cancer in UK collaborative trial of ovarian cancer screening. International Journal of Cancer, 2014, 134, 2180-2188.	5.1	49
111	Osteoprotegerin (OPG), The Endogenous Inhibitor of Receptor Activator of NF-ÎºB Ligand (RANKL), is Dysregulated in BRCA Mutation Carriers. EBioMedicine, 2015, 2, 1331-1339.	6.1	49
112	Methylation patterns in serum DNA for early identification of disseminated breast cancer. Genome Medicine, 2017, 9, 115.	8.2	49
113	Genetic Data from Nearly 63,000 Women of European Descent Predicts DNA Methylation Biomarkers and Epithelial Ovarian Cancer Risk. Cancer Research, 2019, 79, 505-517.	0.9	49
114	Screening practices in cancer survivors. Journal of Cancer Survivorship, 2007, 1, 17-26.	2.9	48
115	Evaluation of Candidate Stromal Epithelial Cross-Talk Genes Identifies Association between Risk of Serous Ovarian Cancer and TERT, a Cancer Susceptibility â€œHot-Spotâ€. PLoS Genetics, 2010, 6, e1001016.	3.5	48
116	Functional Polymorphisms in the TERT Promoter Are Associated with Risk of Serous Epithelial Ovarian and Breast Cancers. PLoS ONE, 2011, 6, e24987.	2.5	48
117	Risk of Ovarian Cancer and the NF-ÎºB Pathway: Genetic Association with IL1A and TNFSF10. Cancer Research, 2014, 74, 852-861.	0.9	48
118	Validating genetic risk associations for ovarian cancer through the international Ovarian Cancer Association Consortium. British Journal of Cancer, 2009, 100, 412-420.	6.4	47
119	Long-term follow-up of cervical disease in women screened by cytology and HPV testing: results from the HART study. British Journal of Cancer, 2010, 102, 1405-1410.	6.4	47
120	The Role of KRAS rs61764370 in Invasive Epithelial Ovarian Cancer: Implications for Clinical Testing. Clinical Cancer Research, 2011, 17, 3742-3750.	7.0	47
121	Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer. Clinical Cancer Research, 2017, 23, 5912-5922.	7.0	47
122	A combined biomarker panel shows improved sensitivity for the early detection of ovarian cancer allowing the identification of the most aggressive type II tumours. British Journal of Cancer, 2017, 117, 666-674.	6.4	47
123	Predictors of complications in gynaecological oncological surgery: a prospective multicentre study (UKGOSOCâ€"UK gynaecological oncology surgical outcomes and complications). British Journal of Cancer, 2015, 112, 475-484.	6.4	45
124	Current detection rates and time-to-detection of all identifiable BRCA carriers in the Greater London population. Journal of Medical Genetics, 2018, 55, 538-545.	3.2	45
125	Randomised trial of populationâ€based <scp>BRCA</scp> testing in Ashkenazi Jews: longâ€term outcomes. BJOG: an International Journal of Obstetrics and Gynaecology, 2020, 127, 364-375.	2.3	45
126	Aberrant regulation of RANKL/OPG in women at high risk of developing breast cancer. Oncotarget, 2017, 8, 3811-3825.	1.8	45

#	Article	IF	Citations
127	Heritage, health and well-being: assessing the impact of a heritage focused intervention on health and well-being. International Journal of Heritage Studies, 2013, 19, 229-242.	1.9	44
128	Common Genetic Variation In Cellular Transport Genes and Epithelial Ovarian Cancer (EOC) Risk. PLoS ONE, 2015, 10, e0128106.	2.5	44
129	Advancedâ€stage cancer and time to diagnosis: An International Cancer Benchmarking Partnership (ICBP) crossâ€sectional study. European Journal of Cancer Care, 2019, 28, e13100.	1.5	44
130	Screening for ovarian cancer. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2002, 16, 469-482.	2.8	43
131	Ovarian cancer symptom awareness and anticipated time to help-seeking for symptoms among UK women. Journal of Family Planning and Reproductive Health Care, 2013, 39, 163-171.	0.8	43
132	PPM1DMosaic Truncating Variants in Ovarian Cancer Cases May Be Treatment-Related Somatic Mutations. Journal of the National Cancer Institute, 2016, 108, djv347.	6.3	43
133	Diagnostic routes and time intervals for patients with colorectal cancer in 10 international jurisdictions; findings from a cross-sectional study from the International Cancer Benchmarking Partnership (ICBP). BMJ Open, 2018, 8, e023870.	1.9	43
134	Development and Validation of the Gene Expression Predictor of High-grade Serous Ovarian Carcinoma Molecular SubTYPE (PrOTYPE). Clinical Cancer Research, 2020, 26, 5411-5423.	7.0	43
135	Germline whole exome sequencing and large-scale replication identifies FANCM as a likely high grade serous ovarian cancer susceptibility gene. Oncotarget, 2017, 8, 50930-50940.	1.8	43
136	Association between invasive ovarian cancer susceptibility and 11 best candidate SNPs from breast cancer genome-wide association study. Human Molecular Genetics, 2009, 18, 2297-2304.	2.9	42
137	Cluster-randomised non-inferiority trial comparing DVD-assisted and traditional genetic counselling in systematic population testing for BRCA1/2 mutations. Journal of Medical Genetics, 2016, 53, 472-480.	3.2	42
138	Screening for ovarian cancer in the general population. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2012, 26, 243-256.	2.8	41
139	Discovery of serum biomarkers of ovarian cancer using complementary proteomic profiling strategies. Proteomics - Clinical Applications, 2014, 8, 982-993.	1.6	41
140	Protein Z: A putative novel biomarker for early detection of ovarian cancer. International Journal of Cancer, 2016, 138, 2984-2992.	5.1	41
141	Impact on mortality and cancer incidence rates of using random invitation from population registers for recruitment to trials. Trials, 2011, 12, 61.	1.6	40
142	Cell-type-specific enrichment of risk-associated regulatory elements at ovarian cancer susceptibility loci. Human Molecular Genetics, 2015, 24, 3595-3607.	2.9	40
143	Cell cycle genes and ovarian cancer susceptibility: a tagSNP analysis. British Journal of Cancer, 2009, 101, 1461-1468.	6.4	39
144	Psychological morbidity associated with ovarian cancer screening: results from more than 23Â000 women in the randomised trial of ovarian cancer screening (<scp>UKCTOCS</scp>). BJOG: an International Journal of Obstetrics and Gynaecology, 2014, 121, 1071-1079.	2.3	39

#	Article	IF	Citations
145	Defining the risk threshold for risk reducing salpingo-oophorectomy for ovarian cancer prevention in low risk postmenopausal women. Gynecologic Oncology, 2015, 139, 487-494.	1.4	39
146	Association Between Menopausal Estrogen-Only Therapy and Ovarian Carcinoma Risk. Obstetrics and Gynecology, 2016, 127, 828-836.	2.4	39
147	Comparison of Longitudinal CA125 Algorithms as a First-Line Screen for Ovarian Cancer in the General Population. Clinical Cancer Research, 2018, 24, 4726-4733.	7.0	39
148	Annual outpatient hysteroscopy and endometrial sampling (OHES) in HNPCC/Lynch syndrome (LS). Archives of Gynecology and Obstetrics, 2012, 286, 1555-1562.	1.7	38
149	Evaluation in pre-diagnosis samples discounts ICAM-1 and TIMP-1 as biomarkers for earlier diagnosis of pancreatic cancer. Journal of Proteomics, 2015, 113, 400-402.	2.4	38
150	Evaluation of polygenic risk scores for ovarian cancer risk prediction in a prospective cohort study. Journal of Medical Genetics, 2018, 55, 546-554.	3.2	38
151	Evidence of a genetic link between endometriosis and ovarian cancer. Fertility and Sterility, 2016, 105, 35-43.e10.	1.0	37
152	Ovarian cancer screening in the general population. Current Opinion in Obstetrics and Gynecology, 2001, 13, 61-64.	2.0	36
153	Decline in use of hormone therapy among postmenopausal women in the United Kingdom. Menopause, 2007, 14, 462-467.	2.0	36
154	Association of serum sex steroid receptor bioactivity and sex steroid hormones with breast cancer risk in postmenopausal women. Endocrine-Related Cancer, 2012, 19, 137-147.	3.1	36
155	Circulating Fatty Acids and Risk of Coronary Heart Disease and Stroke: Individual Participant Data Metaâ€Analysis in Up to 16Â126 Participants. Journal of the American Heart Association, 2020, 9, e013131.	3.7	36
156	Perceptions of Colon Cancer Screening by Stage of Screening Test Adoption. Cancer Nursing, 2007, 30, 178-185.	1.5	35
157	Clinical and pathological associations of PTEN expression in ovarian cancer: a multicentre study from the Ovarian Tumour Tissue Analysis Consortium. British Journal of Cancer, 2020, 123, 793-802.	6.4	35
158	Serum inhibin, activin and follistatin in postmenopausal women with epithelial ovarian carcinoma. BJOG: an International Journal of Obstetrics and Gynaecology, 2000, 107, 1069-1074.	2.3	33
159	Genome-wide Analysis Identifies Novel Loci Associated with Ovarian Cancer Outcomes: Findings from the Ovarian Cancer Association Consortium. Clinical Cancer Research, 2015, 21, 5264-5276.	7.0	33
160	An investigation of routes to cancer diagnosis in 10 international jurisdictions, as part of the International Cancer Benchmarking Partnership: survey development and implementation. BMJ Open, 2016, 6, e009641.	1.9	33
161	Comprehensive epithelial tubo-ovarian cancer risk prediction model incorporating genetic and epidemiological risk factors. Journal of Medical Genetics, 2022, 59, 632-643.	3.2	33
162	A wellâ€characterised peak identification list of MALDI MS profile peaks for human blood serum. Proteomics, 2010, 10, 3388-3392.	2.2	32

#	Article	IF	Citations
163	Assessing the malignant potential of ovarian inclusion cysts in postmenopausal women within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS): a prospective cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2012, 119, 207-219.	2.3	32
164	Cost effectiveness of population based BRCA1 founder mutation testing in Sephardi Jewish women. American Journal of Obstetrics and Gynecology, 2018, 218, 431.e1-431.e12.	1.3	32
165	Diagnosis of epithelial ovarian cancer using a combined protein biomarker panel. British Journal of Cancer, 2019, 121, 483-489.	6.4	32
166	Transcriptomeâ€wide association study of breast cancer risk by estrogenâ€receptor status. Genetic Epidemiology, 2020, 44, 442-468.	1.3	32
167	Peptides Generated Ex Vivo from Serum Proteins by Tumor-Specific Exopeptidases Are Not Useful Biomarkers in Ovarian Cancer. Clinical Chemistry, 2010, 56, 262-271.	3.2	31
168	Feasibility of screening for ovarian cancer using symptoms as selection criteria*. BJOG: an International Journal of Obstetrics and Gynaecology, 2006, 114, 59-64.	2.3	30
169	Awareness of ovarian cancer risk factors, beliefs and attitudes towards screening: baseline survey of 21â€‰715 women participating in the UK Collaborative Trial of Ovarian Cancer Screening. British Journal of Cancer, 2010, 103, 454-461.	6.4	30
170	Recruitment of newly diagnosed ovarian cancer patients proved challenging in a multicentre biobanking study. Journal of Clinical Epidemiology, 2011, 64, 525-530.	5.0	30
171	Identifying hopelessness in population research: a validation study of two brief measures of hopelessness. BMJ Open, 2014, 4, e005093.	1.9	29
172	The cost-effectiveness of screening for ovarian cancer: results from the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). British Journal of Cancer, 2017, 117, 619-627.	6.4	29
173	Ovarian cancer symptoms, routes to diagnosis and survival â€“ Population cohort study in the â€˜no screenâ€™ arm of the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Gynecologic Oncology, 2020, 158, 316-322.	1.4	29
174	Network-Based Integration of GWAS and Gene Expression Identifies a HOX-Centric Network Associated with Serous Ovarian Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1574-1584.	2.5	28
175	The FANCM:p.Arg658* truncating variant is associated with risk of triple-negative breast cancer. Npj Breast Cancer, 2019, 5, 38.	5.2	28
176	Parenclitic networks for predicting ovarian cancer. Oncotarget, 2018, 9, 22717-22726.	1.8	28
177	Ovarian cancer screening in the general population. Ultrasound in Obstetrics and Gynecology, 2000, 15, 350-353.	1.7	26
178	Vascular endothelial growth factor gene polymorphisms and ovarian cancer survival. Gynecologic Oncology, 2010, 119, 479-483.	1.4	26
179	Using Museum Objects to Improve Wellbeing in Mental Health Service Users and Neurological Rehabilitation Clients. British Journal of Occupational Therapy, 2013, 76, 208-216.	0.9	26
180	Enhanced GAB2 Expression Is Associated with Improved Survival in High-Grade Serous Ovarian Cancer and Sensitivity to PI3K Inhibition. Molecular Cancer Therapeutics, 2015, 14, 1495-1503.	4.1	26

#	Article	IF	Citations
181	Metabolic Profiling of Adiponectin Levels in Adults. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	26
182	Population-based targeted sequencing of 54 candidate genes identifiesPALB2as a susceptibility gene for high-grade serous ovarian cancer. Journal of Medical Genetics, 2021, 58, 305-313.	3.2	26
183	Mixed methods evaluation of well-being benefits derived from a heritage-in-health intervention with hospital patients. Arts and Health, 2014, 6, 24-58.	1.6	25
184	Use and perceived efficacy of complementary and alternative medicines after discontinuation of hormone therapy. Menopause, 2015, 22, 384-390.	2.0	25
185	Cigarette smoking is associated with adverse survival among women with ovarian cancer: Results from a pooled analysis of 19 studies. International Journal of Cancer, 2017, 140, 2422-2435.	5.1	25
186	Serum HE4 and diagnosis of ovarian cancer in postmenopausal women with adnexal masses. American Journal of Obstetrics and Gynecology, 2020, 222, 56.e1-56.e17.	1.3	25
187	Common Genetic Variation in Circadian Rhythm Genes and Risk of Epithelial Ovarian Cancer (EOC). Journal of Genetics and Genome Research, 2015, 2, .	0.3	25
188	Ovarian cancer screening. Cmaj, 2004, 171, 323-324.	2.0	24
189	Tagging single-nucleotide polymorphisms in candidate oncogenes and susceptibility to ovarian cancer. British Journal of Cancer, 2009, 100, 993-1001.	6.4	24
190	Genetic Variation in TYMS in the One-Carbon Transfer Pathway Is Associated with Ovarian Carcinoma Types in the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2010, 19, 1822-1830.	2.5	24
191	The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer. Gynecologic Oncology, 2012, 124, 185-191.	1.4	24
192	Common variants at theCHEK2gene locus and risk of epithelial ovarian cancer. Carcinogenesis, 2015, 36, 1341-1353.	2.8	24
193	Hereditary non-polyposis colorectal cancer or Lynch syndrome: the gynaecological perspective. Current Opinion in Obstetrics and Gynecology, 2009, 21, 31-38.	2.0	23
194	Quantitative evidence for wellbeing benefits from a heritage-in-health intervention with hospital patients. International Journal of Art Therapy: Inscape, 2012, 17, 63-79.	1.6	23
195	Genome-wide association study of subtype-specific epithelial ovarian cancer risk alleles using pooled DNA. Human Genetics, 2014, 133, 481-497.	3.8	23
196	Enrichment of putative PAX8 target genes at serous epithelial ovarian cancer susceptibility loci. British Journal of Cancer, 2017, 116, 524-535.	6.4	23
197	Evidence of Altered Glycosylation of Serum Proteins Prior to Pancreatic Cancer Diagnosis. International Journal of Molecular Sciences, 2017, 18, 2670.	4.1	23
198	Setting the Threshold for Surgical Prevention in Women at Increased Risk of Ovarian Cancer. International Journal of Gynecological Cancer, 2018, 28, 34-42.	2.5	23

#	Article	IF	Citations
199	Identification of a serum biomarker panel for the differential diagnosis of cholangiocarcinoma and primary sclerosing cholangitis. Oncotarget, 2018, 9, 17430-17442.	1.8	23
200	Attitude towards and factors affecting uptake of populationâ€based <scp>BRCA</scp> testing in the Ashkenazi Jewish population: a cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2019, 126, 784-794.	2.3	23
201	Polygenic risk modeling for prediction of epithelial ovarian cancer risk. European Journal of Human Genetics, 2022, 30, 349-362.	2.8	23
202	Genetic variation in insulin-like growth factor 2 may play a role in ovarian cancer risk. Human Molecular Genetics, 2011, 20, 2263-2272.	2.9	22
203	Ovarian Cancer Screening and Mortality. JAMA - Journal of the American Medical Association, 2011, 306, 1544.	7.4	22
204	Epithelialâ€Mesenchymal Transition (EMT) Gene Variants and Epithelial Ovarian Cancer (EOC) Risk. Genetic Epidemiology, 2015, 39, 689-697.	1.3	22
205	Serial Patterns of Ovarian Cancer Biomarkers in a Prediagnosis Longitudinal Dataset. BioMed Research International, 2015, 2015, 1-6.	1.9	22
206	MyD88 and TLR4 Expression in Epithelial Ovarian Cancer. Mayo Clinic Proceedings, 2018, 93, 307-320.	3.0	22
207	Riskâ€Reducing Salpingoâ€Oophorectomy and the Use of Hormone Replacement Therapy Below the Age of Natural Menopause. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, .	2.3	22
208	Enhancing Cancer Patient Well-Being With a Nonpharmacological, Heritage-Focused Intervention. Journal of Pain and Symptom Management, 2012, 44, 731-740.	1.2	21
209	Experience of symptoms indicative of gynaecological cancers in UK women. British Journal of Cancer, 2013, 109, 882-887.	6.4	21
210	Large-Scale Evaluation of Common Variation in Regulatory T Cellâ€“Related Genes and Ovarian Cancer Outcome. Cancer Immunology Research, 2014, 2, 332-340.	3.4	21
211	Time to diagnosis of Type I or <scp>II</scp> invasive epithelial ovarian cancers: a multicentre observational study using patient questionnaire and primary care records. BJOG: an International Journal of Obstetrics and Gynaecology, 2016, 123, 1012-1020.	2.3	21
212	Human epididymis protein 4 antigenâ€autoantibody complexes complement cancer antigen 125 for detecting earlyâ€stage ovarian cancer. Cancer, 2020, 126, 725-736.	4.1	21
213	Estrogen Receptor Beta rs1271572 Polymorphism and Invasive Ovarian Carcinoma Risk: Pooled Analysis within the Ovarian Cancer Association Consortium. PLoS ONE, 2011, 6, e20703.	2.5	21
214	Investigating the therapeutic potential of a heritage-object focused intervention: a qualitative study. Journal of Health Psychology, 2012, 17, 809-820.	2.3	20
215	The UKCTOCS Experienceâ€”Reasons for Hope?. International Journal of Gynecological Cancer, 2012, 22, S18-S20.	2.5	20
216	Analysis of Over 10,000 Cases Finds No Association between Previously Reported Candidate Polymorphisms and Ovarian Cancer Outcome. Cancer Epidemiology Biomarkers and Prevention, 2013, 22, 987-992.	2.5	20

#	Article	IF	Citations
217	The association between socioeconomic status and tumour stage at diagnosis of ovarian cancer: A pooled analysis of 18 case-control studies. Cancer Epidemiology, 2016, 41, 71-79.	1.9	20
218	Sexual functioning in 4,418 postmenopausal women participating in UKCTOCS: a qualitative free-text analysis. Menopause, 2019, 26, 1100-1009.	2.0	20
219	MicroRNA Processing and Binding Site Polymorphisms Are Not Replicated in the Ovarian Cancer Association Consortium. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1793-1797.	2.5	19
220	Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Human Genetics, 2016, 135, 741-756.	3.8	19
221	Time intervals and routes to diagnosis for lung cancer in 10 jurisdictions: cross-sectional study findings from the International Cancer Benchmarking Partnership (ICBP). BMJ Open, 2019, 9, e025895.	1.9	19
222	Population Study of Ovarian Cancer Risk Prediction for Targeted Screening and Prevention. Cancers, 2020, 12, 1241.	3.7	19
223	Polymorphism in theIL18Gene and Epithelial Ovarian Cancer in Non-Hispanic White Women. Cancer Epidemiology Biomarkers and Prevention, 2008, 17, 3567-3572.	2.5	18
224	Evaluating the therapeutic effects of museum object handling with hospital patients: A review and initial trial of well-being measures. Journal of Applied Arts and Health, 2011, 2, 37-56.	0.4	18
225	Psychological outcomes of familial ovarian cancer screening: No evidence of long-term harm. Gynecologic Oncology, 2012, 127, 556-563.	1.4	18
226	Acceptance of transvaginal sonography by postmenopausal women participating in the United Kingdom Collaborative Trial of Ovarian Cancer Screening. Ultrasound in Obstetrics and Gynecology, 2013, 41, 73-79.	1.7	18
227	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	1.4	18
228	Multi-Marker Longitudinal Algorithms Incorporating HE4 and CA125 in Ovarian Cancer Screening of Postmenopausal Women. Cancers, 2020, 12, 1931.	3.7	18
229	Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes. EBioMedicine, 2022, 75, 103802.	6.1	18
230	Functional complementation studies identify candidate genes and common genetic variants associated with ovarian cancer survival. Human Molecular Genetics, 2009, 18, 1869-1878.	2.9	17
231	Novel one-stop multidisciplinary follow-up clinic significantly improves cancer risk management in BRCA1/2 carriers. Familial Cancer, 2010, 9, 313-319.	1.9	17
232	Generic well-being outcomes: towards a conceptual framework for well-being outcomes in museums. Museum Management and Curatorship, 2011, 26, 237-259.	1.4	17
233	Exome genotyping arrays to identify rare and low frequency variants associated with epithelial ovarian cancer risk. Human Molecular Genetics, 2016, 25, 3600-3612.	2.9	17
234	Quality assurance and its impact on ovarian visualization rates in the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Ultrasound in Obstetrics and Gynecology, 2016, 47, 228-235.	1.7	17

#	Article	IF	Citations
235	Complementary Longitudinal Serum Biomarkers to CA125 for Early Detection of Ovarian Cancer. Cancer Prevention Research, 2019, 12, 391-400.	1.5	17
236	Ovarian cancer: challenges of early detection. Nature Clinical Practice Oncology, 2007, 4, 498-499.	4.3	16
237	Consortium analysis of gene and geneâ€"folate interactions in purine and pyrimidine metabolism pathways with ovarian carcinoma risk. Molecular Nutrition and Food Research, 2014, 58, 2023-2035.	3.3	16
238	Refining Ovarian Cancer Test accuracy Scores (ROCkeTS): protocol for a prospective longitudinal test accuracy study to validate new risk scores in women with symptoms of suspected ovarian cancer. BMJ Open, 2016, 6, e010333.	1.9	16
239	Sex hormone measurements using mass spectrometry and sensitive extraction radioimmunoassay and risk of estrogen receptor negative and positive breast cancer: Case control study in UK Collaborative Cancer Trial of Ovarian Cancer Screening (UKCTOCS). Steroids, 2016, 110, 62-69.	1.8	16
240	A quantitative performance study of two automatic methods for the diagnosis of ovarian cancer. Biomedical Signal Processing and Control, 2018, 46, 86-93.	5.7	16
241	Serum Proteomic Abnormality Predating Screen Detection of Ovarian Cancer. Computer Journal, 2009, 52, 326-333.	2.4	15
242	The Sine Qua Non of Discovering Novel Biomarkers for Early Detection of Ovarian Cancer: Carefully Selected Preclinical Samples. Cancer Prevention Research, 2011, 4, 299-302.	1.5	15
243	Patient-reporting improves estimates of postoperative complication rates: a prospective cohort study in gynaecological oncology. British Journal of Cancer, 2013, 109, 623-632.	6.4	15
244	Validity of self-reported hysterectomy: a prospective cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). BMJ Open, 2014, 4, e004421.	1.9	15
245	Evaluating the ovarian cancer gonadotropin hypothesis: A candidate gene study. Gynecologic Oncology, 2015, 136, 542-548.	1.4	15
246	Adult height is associated with increased risk of ovarian cancer: a Mendelian randomisation study. British Journal of Cancer, 2018, 118, 1123-1129.	6.4	15
247	Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. International Journal of Epidemiology, 2018, 47, 450-459.	1.9	15
248	Menopausal hormone therapy prior to the diagnosis of ovarian cancer is associated with improved survival. Gynecologic Oncology, 2020, 158, 702-709.	1.4	15
249	Common variants in breast cancer risk loci predispose to distinct tumor subtypes. Breast Cancer Research, 2022, 24, 2.	5.0	15
250	Validated biomarker assays confirm that <scp>ARID1A</scp> loss is confounded with <scp>MMR</scp> deficiency, <scp>CD8⁺ TIL</scp> infiltration, and provides no independent prognostic value in endometriosisâ€associated ovarian carcinomas. Journal of Pathology, 2022, 256, 388-401.	4.5	15
251	A comparison of national cancer registry and direct follow-up in the ascertainment of ovarian cancer. British Journal of Cancer, 1999, 80, 1826-1827.	6.4	14
252	Screening for ovarian cancer. Expert Review of Anticancer Therapy, 2003, 3, 55-62.	2.4	14

#	Article	IF	Citations
253	Conformal predictors in early diagnostics of ovarian and breast cancers. Progress in Artificial Intelligence, 2012, 1, 245-257.	2.4	14
254	Factors affecting visualization of postmenopausal ovaries: descriptive study from the multicenter United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Ultrasound in Obstetrics and Gynecology, 2013, 42, 472-477.	1.7	14
255	Risk reducing salpingectomy and delayed oophorectomy in high risk women: views of cancer geneticists, genetic counsellors and gynaecological oncologists in the UK. Familial Cancer, 2015, 14, 521-530.	1.9	14
256	Ovarian cancer screening: UKCTOCS trial â€“ Authors' reply. Lancet, The, 2016, 387, 2603-2604.	13.7	14
257	Factors Affecting Short-term Mortality in Women With Ovarian, Tubal, or Primary Peritoneal Cancer: Population-Based Cohort Analysis of English National Cancer Registration Data. International Journal of Gynecological Cancer, 2016, 26, 56-65.	2.5	14
258	Can Ovarian Cancer Screening Save Lives? The Question Remains Unanswered. Obstetrics and Gynecology, 2011, 118, 1209-1211.	2.4	13
259	Variation in NF-ÎºB Signaling Pathways and Survival in Invasive Epithelial Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 1421-1427.	2.5	13
260	Use of common analgesic medications and ovarian cancer survival: results from a pooled analysis in the Ovarian Cancer Association Consortium. British Journal of Cancer, 2017, 116, 1223-1228.	6.4	13
261	Change-point of multiple biomarkers in women with ovarian cancer. Biomedical Signal Processing and Control, 2017, 33, 169-177.	5.7	13
262	Riskâ€reducing early salpingectomy and delayed oophorectomy as a twoâ€staged alternative for primary prevention of ovarian cancer in women at increased risk: a commentary. BJOG: an International Journal of Obstetrics and Gynaecology, 2019, 126, 831-839.	2.3	13
263	Attitudes towards riskâ€reducing early salpingectomy with delayed oophorectomy for ovarian cancer prevention: a cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2021, 128, 714-726.	2.3	13
264	Inherited variants affecting RNA editing may contribute to ovarian cancer susceptibility: results from a large-scale collaboration. Oncotarget, 2016, 7, 72381-72394.	1.8	13
265	Novel risk models for early detection and screening of ovarian cancer. Oncotarget, 2017, 8, 785-797.	1.8	13
266	Withdrawal from familial ovarian cancer screening for surgery: Findings from a psychological evaluation study (PsyFOCS). Gynecologic Oncology, 2012, 124, 158-163.	1.4	12
267	A comprehensive geneâ€“environment interaction analysis in Ovarian Cancer using genomeâ€wide significant common variants. International Journal of Cancer, 2019, 144, 2192-2205.	5.1	12
268	Cross-Cancer Genome-Wide Association Study of Endometrial Cancer and Epithelial Ovarian Cancer Identifies Genetic Risk Regions Associated with Risk of Both Cancers. Cancer Epidemiology Biomarkers and Prevention, 2021, 30, 217-228.	2.5	12
269	Screening for gynaecological cancers. European Journal of Surgical Oncology, 2006, 32, 818-824.	1.0	11
270	Serum oestrogen receptor Î± and Î² bioactivity are independently associated with breast cancer: a proof of principle study. British Journal of Cancer, 2009, 101, 160-165.	6.4	11

#	Article	IF	Citations
271	Risk of chronic liver disease in post-menopausal women due to body mass index, alcohol and their interaction: a prospective nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). BMC Public Health, 2017, 17, 603.	2.9	11
272	Highly accurate detection of ovarian cancer using CA125 but limited improvement with serum matrix-assisted laser desorption/ionization time-of-flight mass spectrometry profiling. International Journal of Gynecological Cancer, 2010, 20, 1518-24.	2.5	11
273	Ovarian cancer screening. British Journal of Hospital Medicine, 2002, 63, 210-213.	0.2	10
274	Postmenopausal women undergoing transvaginal ultrasound screening prefer not to have chaperones. BJOG: an International Journal of Obstetrics and Gynaecology, 2006, 113, 954-957.	2.3	10
275	Psychosocial Factors Associated With Withdrawal From the United Kingdom Collaborative Trial of Ovarian Cancer Screening After 1 Episode of Repeat Screening. International Journal of Gynecological Cancer, 2015, 25, 1519-1525.	2.5	10
276	Assessment of Multifactor Geneâ€“Environment Interactions and Ovarian Cancer Risk: Candidate Genes, Obesity, and Hormone-Related Risk Factors. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 780-790.	2.5	10
277	Sonographers' self-reported visualization of normal postmenopausal ovaries on transvaginal ultrasound is not reliable: results of expert review of archived images from UKCTOCS. Ultrasound in Obstetrics and Gynecology, 2018, 51, 401-408.	1.7	10
278	Agreement between questionnaires and registry data on routes to diagnosis and milestone dates of the cancer diagnostic pathway. Cancer Epidemiology, 2020, 65, 101690.	1.9	10
279	Socioeconomic indicators of health inequalities and female mortality: a nested cohort study within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). BMC Public Health, 2015, 15, 253.	2.9	9
280	Multiprobabilistic prediction in early medical diagnoses. Annals of Mathematics and Artificial Intelligence, 2015, 74, 203-222.	1.3	9
281	Investigation of Exomic Variants Associated with Overall Survival in Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2016, 25, 446-454.	2.5	9
282	Variants in genes encoding small GTPases and association with epithelial ovarian cancer susceptibility. PLoS ONE, 2018, 13, e0197561.	2.5	9
283	Surgical decision making in premenopausal BRCA carriers considering risk-reducing early salpingectomy or salpingo-oophorectomy: a qualitative study. Journal of Medical Genetics, 2021, , jmedgenet-2020-107501.	3.2	9
284	Mendelian randomisation study of smoking exposure in relation to breast cancer risk. British Journal of Cancer, 2021, 125, 1135-1145.	6.4	9
285	Familial ovarian screening â€“ effective or ineffective?. British Journal of Cancer, 2006, 95, 1124-1124.	6.4	8
286	Mathematical Models to Discriminate Between Benign and Malignant Adnexal Masses: Potential Diagnostic Improvement Using Ovarian HistoScanning. International Journal of Gynecological Cancer, 2011, 21, 35-43.	2.5	8
287	Genome-Wide Association Study for Ovarian Cancer Susceptibility Using Pooled DNA. Twin Research and Human Genetics, 2012, 15, 615-623.	0.6	8
288	Concordance of National Cancer Registration with self-reported breast, bowel and lung cancer in England and Wales: a prospective cohort study within the UK Collaborative Trial of Ovarian Cancer Screening. British Journal of Cancer, 2013, 109, 2875-2879.	6.4	8

#	Article	IF	Citations
289	Association of skirt size and postmenopausal breast cancer risk in older women: a cohort study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). BMJ Open, 2014, 4, e005400-e005400.	1.9	8
290	Long-Term Secondary Care Costs of Endometrial Cancer: A Prospective Cohort Study Nested within the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). PLoS ONE, 2016, 11, e0165539.	2.5	8
291	The effect of ovarian cancer screening on sexual activity and functioning: results from the UK collaborative trial of ovarian cancer screening RCT. British Journal of Cancer, 2017, 116, 1111-1117.	6.4	8
292	Changing trends in reproductive/lifestyle factors in UK women: descriptive study within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). BMJ Open, 2017, 7, e011822.	1.9	8
293	Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. American Journal of Epidemiology, 2018, 187, 366-377.	3.4	8
294	Expanding Our Understanding of Ovarian Cancer Risk: The Role of Incomplete Pregnancies. Journal of the National Cancer Institute, 2021, 113, 301-308.	6.3	8
295	A polymorphism in the GALNT2 gene and ovarian cancer risk in four population based case-control studies. International Journal of Molecular Epidemiology and Genetics, 2010, 1, 272-7.	0.4	8
296	Gene Set Analysis of Survival Following Ovarian Cancer Implicates Macrolide Binding and Intracellular Signaling Genes. Cancer Epidemiology Biomarkers and Prevention, 2012, 21, 529-536.	2.5	7
297	Ovarian cancer screening has no effect on disease-specific mortality. Evidence-Based Medicine, 2012, 17, 47-48.	0.6	7
298	Diathermy-Induced Injury May Affect Detection of Occult Tubal Lesions at Risk-Reducing Salpingo-Oophorectomy. International Journal of Gynecological Cancer, 2012, 22, 881-888.	2.5	7
299	Performance of ultrasound as a second line test to serum CA125 in ovarian cancer screening. BJOG: an International Journal of Obstetrics and Gynaecology, 2014, 121, 35-39.	2.3	7
300	Should Opportunistic Bilateral Salpingectomy (OBS) for Prevention of Ovarian Cancer Be Incorporated Into Routine Care or Offered in the Context of a Clinical Trial?. International Journal of Gynecological Cancer, 2016, 26, 31-33.	2.5	7
301	A splicing variant of TERT identified by GWAS interacts with menopausal estrogen therapy in risk of ovarian cancer. International Journal of Cancer, 2016, 139, 2646-2654.	5.1	7
302	Commentary on changing the risk threshold for surgical prevention of ovarian cancer. BJOG: an International Journal of Obstetrics and Gynaecology, 2018, 125, 541-544.	2.3	7
303	The 14q32 maternally imprinted locus is a major source of longitudinally stable circulating microRNAs as measured by small RNA sequencing. Scientific Reports, 2019, 9, 15787.	3.3	7
304	Colorectal cancer ascertainment through cancer registries, hospital episode statistics, and self-reporting compared to confirmation by clinician: A cohort study nested within the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Cancer Epidemiology, 2019, 58, 167-174.	1.9	7
305	Completeness and accuracy of national cancer and death registration for outcome ascertainment in trialsâ€"an ovarian cancer exemplar. Trials, 2021, 22, 88.	1.6	7
306	Evaluation of vitamin D biosynthesis and pathway target genes reveals UGT2A1/2 and EGFR polymorphisms associated with epithelial ovarian cancer in African American Women. Cancer Medicine, 2019, 8, 2503-2513.	2.8	6

#	Article	IF	Citations
307	Performance Characteristics of the Ultrasound Strategy during Incidence Screening in the UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). Cancers, 2021, 13, 858.	3.7	6
308	Joint IARC/NCI International Cancer Seminar Series Report: expert consensus on future directions for ovarian carcinoma research. Carcinogenesis, 2021, 42, 785-793.	2.8	6
309	Functional annotation of the 2q35 breast cancer risk locus implicates a structural variant in influencing activity of a long-range enhancer element. American Journal of Human Genetics, 2021, 108, 1190-1203.	6.2	6
310	Early detection of ovarian cancer in samples pre-diagnosis using CA125 and MALDI-MS peaks. Cancer Genomics and Proteomics, 2011, 8, 289-305.	2.0	6
311	Ovarian cancer. BMJ: British Medical Journal, 2009, 339, b4650-b4650.	2.3	5
312	Psychosocial risk profiles among black male veterans administration patients nonâ€adherent with colorectal cancer screening. Psycho-Oncology, 2011, 20, 1151-1160.	2.3	5
313	Adapting the coping in deliberation (CODE) framework: A multi-method approach in the context of familial ovarian cancer risk management. Patient Education and Counseling, 2014, 97, 200-210.	2.2	5
314	Benchmarking of surgical complications in gynaecological oncology: prospective multicentre study. BJOG: an International Journal of Obstetrics and Gynaecology, 2016, 123, 2171-2180.	2.3	5
315	Influences on anticipated time to ovarian cancer symptom presentation in women at increased risk compared to population risk of ovarian cancer. BMC Cancer, 2017, 17, 814.	2.6	5
316	Two truncating variants in FANCC and breast cancer risk. Scientific Reports, 2019, 9, 12524.	3.3	5
317	Socioeconomic Status and Ovarian Cancer Stage at Diagnosis: A Study Nested Within UKCTOCS. Diagnostics, 2020, 10, 89.	2.6	5
318	The Enhanced Liver Fibrosis test is associated with liver-related outcomes in postmenopausal women with risk factors for liver disease. BMC Gastroenterology, 2020, 20, 104.	2.0	5
319	Multiprobabilistic Venn Predictors with Logistic Regression. International Federation for Information Processing, 2012, , 224-233.	0.4	5
320	Polymorphisms in Stromal Genes and Susceptibility to Serous Epithelial Ovarian Cancer: A Report from the Ovarian Cancer Association Consortium. PLoS ONE, 2011, 6, e19642.	2.5	5
321	Assessment of variation in immunosuppressive pathway genes reveals TGFBR2 to be associated with risk of clear cell ovarian cancer. Oncotarget, 2016, 7, 69097-69110.	1.8	5
322	Epithelial ovarian cancer and induction of ovulation. Reviews in Gynaecological Practice, 2005, 5, 131-138.	0.1	4
323	Histological confirmation of breast cancer registration and self-reporting in England and Wales: a cohort study within the UK Collaborative Trial of Ovarian Cancer Screening. British Journal of Cancer, 2012, 106, 1910-1916.	6.4	4
324	Screening of symptomatic women for ovarian cancer. Lancet Oncology, The, 2012, 13, e138-e139.	10.7	4

#	Article	IF	Citations
325	UKCTOCS update: applying insights of delayed effects in cancer screening trials to the long-term follow-up mortality analysis. Trials, 2021, 22, 173.	1.6	4
326	Diagnostic routes and time intervals for ovarian cancer in nine international jurisdictions; findings from the International Cancer Benchmarking Partnership (ICBP). British Journal of Cancer, 2022, 127, 844-854.	6.4	4
327	Randomised trial of populationâ€based <scp>BRCA</scp> testing in Ashkenazi Jews: longâ€term secondary lifestyle behavioural outcomes. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 1970-1980.	2.3	4
328	Evaluation of Plasma Fructosamine as a Screening Test for Gestational Diabetes. Australian and New Zealand Journal of Obstetrics and Gynaecology, 1991, 31, 25-26.	1.0	3
329	Screening for familial ovarian cancer. , 2002, , 220-234.		3
330	Screening for ovarian cancer. Reviews in Gynaecological Practice, 2004, 4, 156-161.	0.1	3
331	Preimplantation Genetic Diagnosis for Hereditary Cancers. Advances in Experimental Medicine and Biology, 2012, 732, 103-113.	1.6	3
332	No Evidence That Genetic Variation in the Myeloid-Derived Suppressor Cell Pathway Influences Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2017, 26, 420-424.	2.5	3
333	rs495139 in the TYMS-ENOSF1 Region and Risk of Ovarian Carcinoma of Mucinous Histology. International Journal of Molecular Sciences, 2018, 19, 2473.	4.1	3
334	Jewish cultural and religious factors and uptake of populationâ€based BRCA testing across denominations: a cohort study. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 959-968.	2.3	3
335	Unselected Population Genetic Testing for Personalised Ovarian Cancer Risk Prediction: A Qualitative Study Using Semi-Structured Interviews. Diagnostics, 2022, 12, 1028.	2.6	3
336	Importance of serial CA125 measurements over an absolute cutâ€off value for the detection of asymptomatic ovarian cancer in highâ€risk patients. International Journal of Gynecology and Obstetrics, 2016, 133, 239-240.	2.3	2
337	Serial endometrial thickness and risk of nonâ€endometrial hormoneâ€dependent cancers in postmenopausal women in UK Collaborative Trial of Ovarian Cancer Screening. Ultrasound in Obstetrics and Gynecology, 2020, 56, 267-275.	1.7	2
338	Offspring sex and risk of epithelial ovarian cancer: a multinational pooled analysis of 12 caseâ€“control studies. European Journal of Epidemiology, 2020, 35, 1025-1042.	5.7	2
339	Germline HOXB13 mutations p.G84E and p.R217C do not confer an increased breast cancer risk. Scientific Reports, 2020, 10, 9688.	3.3	2
340	Association of hysterectomy and invasive epithelial ovarian and tubal cancer: a cohort study within UKCTOCS. BJOG: an International Journal of Obstetrics and Gynaecology, 2022, 129, 110-118.	2.3	2
341	CA125 and Other Tumor Markers in Screening and Monitoring of Ovarian Cancer. , 2003, , 193-200.		2
342	Audit of transvaginal sonography of normal postmenopausal ovaries by sonographers from the United Kingdom Collaborative Trial of Ovarian Cancer Screening (UKCTOCS). F1000Research, 2018, 7, 1241.	1.6	2

#	Article	IF	Citations
343	High Prediagnosis Inflammation-Related Risk Score Associated with Decreased Ovarian Cancer Survival. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 443-452.	2.5	2
344	Registration of ovarian cancer in England and Wales. British Journal of Cancer, 2000, 83, 279-279.	6.4	1
345	Ovarian Cancer Screening. , 2006, , 47-68.		1
346	The value of ovarian cancer screening. British Journal of Hospital Medicine (London, England: 2005), 2006, 67, 314-317.	0.5	1
347	There is a need for routine peritoneal cytology at RRSO. Gynecologic Oncology, 2013, 128, 149-150.	1.4	1
348	Screening for gynecological cancers. Expert Review of Obstetrics and Gynecology, 2013, 8, 143-160.	0.4	1
349	Steps towards effective gynaecological cancer screening. Nature Reviews Clinical Oncology, 2018, 15, 538-540.	27.6	1
350	Reproductive factors do not influence survival with ovarian cancer. Cancer Epidemiology Biomarkers and Prevention, 2022, , cebp.1091.2021.	2.5	1
351	Serum markers for gynaecological cancer in the reproductive years. , 0, , 155-178.		0
352	Screening for Ovarian Cancer. , 0, , 144-150.		0
353	Prostate Cancer Susceptibility Polymorphism rs2660753 Is Not Associated with Invasive Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 1028-1031.	2.5	0
354	Screening for Gynaecological Cancers. , 2015, , 267-281.		0
355	The double-edged sword of ovarian cancer information for women at increased risk who have previously taken part in screening. Ecancermedicalscience, 2016, 10, 650.	1.1	0
356	Reply to P.F. Pinsky, C.P. Crum, and M.W. McIntosh et al. Journal of Clinical Oncology, 2016, 34, 201-202.	1.6	0
357	Association between skirt size and chronic liver disease in post-menopausal women: a prospective cohort study within the United Kingdom Trial of Ovarian Cancer Screening (UKCTOCS). BMC Public Health, 2018, 18, 409.	2.9	0
358	Association of adult attachment with delays in accessing specialist care in women with ovarian cancer. Journal of Psychosocial Oncology, 2022, 40, 491-505.	1.2	0